Drugs / GenHevac B Pasteur
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00480792 | Jun 2007 → Dec 2008 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT01698866 | Jul 2012 → Jul 2017 | atypical lymphoproliferative disorder | Central Hospital, Nancy, France | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GenHevac B Pasteur | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00480792 ↗ |
| Known as | GenHevac-B | “GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6” NCT00480792 ↗ |
| Modality | Vaccine | “recombinant HBV vaccine” PMID 27064975 ↗ May 2016 |
| Route | Intramuscular | “Intramuscular use” NCT00480792 ↗ |